 <h1>Cresemba Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>isavuconazonium</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about isavuconazonium. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Cresemba.</p><h2>In Summary</h2><p><b>Common side effects of Cresemba include:</b> dyspnea, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, and increased serum bilirubin. <b>Other side effects include:</b> hypotension.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to isavuconazonium: oral capsule</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, isavuconazonium (the active ingredient contained in Cresemba) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking isavuconazonium:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody urine</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>confusion</li>
<li>convulsions</li>
<li>decreased frequency or amount of urine</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast or irregular heartbeat</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle pain or cramps</li>
<li>muscle spasms (tetany) or twitching</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>seizures</li>
<li>severe nausea or vomiting</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trembling</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Cough or hoarseness</li>
<li>dark urine</li>
<li>fever with or without chills</li>
<li>hives, itching, or rash</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>light-colored stools</li>
<li>red, swollen skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stomach pain</li>
<li>unusual bleeding or bruising</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chills</li>
<li>diarrhea</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of isavuconazonium may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>anxiety</li>
<li>back pain</li>
<li>headache</li>
<li>heartburn or indigestion</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>stomach discomfort or upset</li>
<li>trouble sleeping</li>
<li>unusual excitement, nervousness, or restlessness</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>Continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>decreased vision</li>
<li>eye pain</li>
<li>feeling of constant movement of self or surroundings</li>
<li>hair loss or thinning of the hair</li>
<li>hearing loss</li>
<li>sensation of spinning</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isavuconazonium: intravenous powder for injection, oral capsule</i></p><h3>General</h3><p>The most common side effects were nausea, vomiting, diarrhea, headache, elevated liver chemistry tests, hypokalemia, constipation, dyspnea, cough, peripheral edema, back pain, abdominal pain, injection site reaction, and rash.  Serious side effects were reported in 55% of patients.  Therapy was permanently discontinued due to side effects in 14% of patients; confusional state, acute renal failure, increased blood bilirubin, convulsion, dyspnea, epilepsy, respiratory failure, and vomiting led to permanent discontinuation most often.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 27.6%), vomiting (up to 25%), diarrhea (up to 23.7%), abdominal pain (16.7%), constipation (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal distension</p>
<p><b>Frequency not reported</b>: Gastritis, gingivitis, stomatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (up to 19.1%)</p>
<p><b>Common</b> (1% to 10%): Decreased appetite, hypomagnesemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoalbuminemia, hypoglycemia, malnutrition</p>
<p><b>Frequency not reported</b>: Hyponatremia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated liver chemistry/laboratory tests (includes increased ALT, increased AST, increased blood alkaline phosphatase, increased blood bilirubin, increased blood lactate dehydrogenase, increased GGT, increased hepatic enzyme, abnormal hepatic function, hyperbilirubinemia, abnormal liver function test, increased transaminases; up to 17.1%)</p>
<p><b>Common</b> (1% to 10%): Elevated liver transaminases (ALT or AST)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatitis, hepatomegaly</p>
<p><b>Frequency not reported</b>: Cholecystitis, cholelithiasis, hepatic failure, cholestasis<sup>[Ref]</sup></p><p>Elevated liver transaminases (ALT or AST) greater than 3 times the upper limit of normal (3 x ULN) and greater than 10 x ULN were reported in 4.4% and 1.2% of patients, respectively.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 17.1%), cough (12%)</p>
<p><b>Common</b> (1% to 10%): Acute respiratory failure</p>
<p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, tachypnea, hemoptysis, epistaxis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Convulsion, syncope, dizziness, paresthesia, encephalopathy, presyncope, peripheral neuropathy, dysgeusia, vertigo</p>
<p><b>Frequency not reported</b>: Epilepsy, hypoesthesia, migraine, stupor, tremor, tinnitus<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 15.2%), fatigue (10.5%)</p>
<p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Malaise, asthenia</p>
<p><b>Frequency not reported</b>: Infusion-related reactions (including hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia), catheter thrombosis, chills, fall<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (10.5%)</p>
<p><b>Common</b> (1% to 10%): Delirium (includes agitation, confusional state, delirium, disorientation, mental status changes), anxiety</p>
<p><b>Uncommon</b> (0.1% to 1%): Depression</p>
<p><b>Frequency not reported</b>: Confusion, hallucination<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal failure (10.1%)</p>
<p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 10.1%)</p>
<p><b>Frequency not reported</b>: Myositis, bone pain, neck pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, thrombophlebitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, atrial flutter, bradycardia, reduced QT interval on ECG/shortened ECG QT, palpitations, supraventricular extrasystoles, supraventricular tachycardia, tachycardia, ventricular extrasystoles, circulatory collapse</p>
<p><b>Frequency not reported</b>: Cardiac arrest<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, dermatitis, petechiae, drug eruption</p>
<p><b>Frequency not reported</b>: Exfoliative dermatitis, erythema, urticaria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Neutropenia, thrombocytopenia, leukopenia, pancytopenia, anemia</p>
<p><b>Frequency not reported</b>: Agranulocytosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Hematuria, proteinuria<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Optic neuropathy<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Cresemba (isavuconazonium)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: azole antifungals</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cresemba &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Cresemba Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Aspergillosis, Invasive</li>
<li>Mucormycosis, Invasive</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to isavuconazonium: intravenous powder for injection, oral capsule</i></p><h3>General</h3><p>The most common side effects were nausea, vomiting, diarrhea, headache, elevated liver chemistry tests, hypokalemia, constipation, dyspnea, cough, peripheral edema, back pain, abdominal pain, injection site reaction, and rash.  Serious side effects were reported in 55% of patients.  Therapy was permanently discontinued due to side effects in 14% of patients; confusional state, acute renal failure, increased blood bilirubin, convulsion, dyspnea, epilepsy, respiratory failure, and vomiting led to permanent discontinuation most often.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 27.6%), vomiting (up to 25%), diarrhea (up to 23.7%), abdominal pain (16.7%), constipation (up to 14%)</p><p><b>Common</b> (1% to 10%): Dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal distension</p><p><b>Frequency not reported</b>: Gastritis, gingivitis, stomatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (up to 19.1%)</p><p><b>Common</b> (1% to 10%): Decreased appetite, hypomagnesemia</p><p><b>Uncommon</b> (0.1% to 1%): Hypoalbuminemia, hypoglycemia, malnutrition</p><p><b>Frequency not reported</b>: Hyponatremia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated liver chemistry/laboratory tests (includes increased ALT, increased AST, increased blood alkaline phosphatase, increased blood bilirubin, increased blood lactate dehydrogenase, increased GGT, increased hepatic enzyme, abnormal hepatic function, hyperbilirubinemia, abnormal liver function test, increased transaminases; up to 17.1%)</p><p><b>Common</b> (1% to 10%): Elevated liver transaminases (ALT or AST)</p><p><b>Uncommon</b> (0.1% to 1%): Hepatitis, hepatomegaly</p><p><b>Frequency not reported</b>: Cholecystitis, cholelithiasis, hepatic failure, cholestasis<sup>[Ref]</sup></p><p>Elevated liver transaminases (ALT or AST) greater than 3 times the upper limit of normal (3 x ULN) and greater than 10 x ULN were reported in 4.4% and 1.2% of patients, respectively.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 17.1%), cough (12%)</p><p><b>Common</b> (1% to 10%): Acute respiratory failure</p><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, tachypnea, hemoptysis, epistaxis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 17%)</p><p><b>Common</b> (1% to 10%): Somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Convulsion, syncope, dizziness, paresthesia, encephalopathy, presyncope, peripheral neuropathy, dysgeusia, vertigo</p><p><b>Frequency not reported</b>: Epilepsy, hypoesthesia, migraine, stupor, tremor, tinnitus<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 15.2%), fatigue (10.5%)</p><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Malaise, asthenia</p><p><b>Frequency not reported</b>: Infusion-related reactions (including hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia), catheter thrombosis, chills, fall<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (10.5%)</p><p><b>Common</b> (1% to 10%): Delirium (includes agitation, confusional state, delirium, disorientation, mental status changes), anxiety</p><p><b>Uncommon</b> (0.1% to 1%): Depression</p><p><b>Frequency not reported</b>: Confusion, hallucination<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal failure (10.1%)</p><p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 10.1%)</p><p><b>Frequency not reported</b>: Myositis, bone pain, neck pain<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, thrombophlebitis</p><p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, atrial flutter, bradycardia, reduced QT interval on ECG/shortened ECG QT, palpitations, supraventricular extrasystoles, supraventricular tachycardia, tachycardia, ventricular extrasystoles, circulatory collapse</p><p><b>Frequency not reported</b>: Cardiac arrest<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, dermatitis, petechiae, drug eruption</p><p><b>Frequency not reported</b>: Exfoliative dermatitis, erythema, urticaria<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Neutropenia, thrombocytopenia, leukopenia, pancytopenia, anemia</p><p><b>Frequency not reported</b>: Agranulocytosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Hematuria, proteinuria<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Optic neuropathy<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Cresemba (isavuconazonium)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: azole antifungals</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cresemba &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Cresemba Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Aspergillosis, Invasive</li>
<li>Mucormycosis, Invasive</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>